Effects of doxorubicin, 4′-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes

Canadian Journal of Physiology and Pharmacology

Volumn 74, Issue 8, 1996, Pages 904-910

  Chan, E Michelle ^a   Thomas, Marion J ^a   Bandy, Brian ^a   Tibbits, Glen F ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

4 epirubicin; Doxorubicin; Isolated cardiomyocytes; Myocardial contractility; Oxygen radicals

Indexed keywords

ANTIOXIDANT; CATALASE; DOXORUBICIN; EPIRUBICIN; HYDROGEN PEROXIDE; HYDROXYL RADICAL; OXYGEN RADICAL; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CATALASE; CELLS, CULTURED; DEPRESSION, CHEMICAL; DOXORUBICIN; EPIRUBICIN; FEMALE; FREE RADICAL SCAVENGERS; MYOCARDIAL CONTRACTION; MYOCARDIUM; RATS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 0030451779     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y96-091     Document Type: Article

References (54)

1. Ahmed, N.K., Felsted, R.L., and Bachur, N.R. 1978. Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochem. Pharmacol. 27: 2713-2719.
2. Arcamone, F., Cassinelli, G., Franceschi, G., Penco, S., Pol, C., Redaelli, S., and Selva, A. 1972. Structure and physicochemical properties of adriamycin (doxorubicin). In International Symposium on Adriamycin. Edited by S.K. Carter, A. Di Marco, M. Ghione, H. Krakoff, and G. Mathe. Springer-Verlag, Berlin, Heidelberg, New York. pp. 9-22.
3. Azuma, J., Sperelakis, N., Hasegawa, H., Tanimoto, T., Vogel, S., Ogura, K., Awata, N., Sawamura, A., Harada, H., Ishiyama T., Morita, Y., and Yamamura, Y. 1981. Adriamycin cardiotoxicity: possible pathogenic mechanisms. J. Mol. Cell. Cardiol. 13: 381-397.
4. Bandy, B., Moon, J., and Davison, A.J. 1990. Multiple actions of superoxide dismutase: Why can it both inhibit and stimulate reduction of oxygen by hydroquinones? Free Radical Biol. Med. 9:143-148.
5. 2 in isolated canine myocytes. In Oxygen radicals in biology and medicine. Plenum Publishing Corporation, New York. pp. 927-932.
6. Bertazzoli, C., Rovero, C., Ballerini, L., Lux, B., Balconi, F., Antongiovanni, V., and Magrini, U. 1985. Experimental systemic toxicology of 4′-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol. Appl. Pharmacol. 79: 412-422.
7. Buettner, G.R. 1988. In the absence of catalytic metals ascorbate does not autoxidize at pH 7: ascorbate as a test for catalytic metals. J. Biochem. Biophys. Methods, 16: 27-40.
8. Butler, J., Hoey, B.M., and Swallow, A.J. 1985. Reactions of the semiquinone free radicals of anti-tumor agents with oxygen and iron complexes. FEBS Lett. 182(1): 95-98.
9. Cadenas, E., and Ernster, L. 1990. Effect of superoxide dismutase on the autoxidation of hydroquinones formed during DT-diaphorase catalysis and glutathione nucleophilic addition. Antioxid. Ther. Prev. Med. 264: 37-44.
10. Cadenas, E., Mira, D., Brunmark, A., Lind, C., Segura-Aguilar, J., and Ernster, L. 1988. Effect of superoxide dismutase on the autoxidation of various hydroquinones - a possible role of superoxide dismutase as a superoxide:semiquinone oxidoreductase. Free Radical Biol. Med. 5: 71-79.
11. Casazza, A.M., Di Marco, A., Bertazzoli, C., Formelli, F., Giuliani, F., and Pratesi, G. 1978. Antitumor activity, toxicity, and pharmacological properties of 4′-epiadriamycin. In Current chemotherapy. American Society for Microbiologists, International Society of Chemotherapy, Washington. pp. 1257-1260.
12. Dalmark, M., and Storm, H.H. 1981. A Fickian diffusion transport process with features of transport catalysis: doxorubicin transport in human red blood cells. J. Gen. Physiol. 78: 349-364.
13. Davies, K.J.A., and Doroshow, J.H. 1986. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261: 3060-3067.
14. Demant, E.J.F. 1984. Transfer of ferritin-bound iron to adriamycin. FEBS Lett. 176(1): 97-100.
15. Doroshow, J.H. 1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43: 460-472.
16. Ganzina, F. 1983. 4′-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat. Rev. 10: 1-22.
17. Gianni, L., Vigano, L., Lanzi, C., Niggeler, M., and Malatesta, V. 1988. Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines. J. Natl. Cancer Inst. 80: 1104-1111.
18. Grankvist, J., and Henriksson, R. 1987. Doxorubicin and epirubicin iron-induced generation of free radicals in vitro. A comparative study. Biosci. Rep. 7: 653-658.
19. Greene, R.F., Collins, J.M., Jenkins, J.F., Speyer, J.L., and Myers, C.E. 1983. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 43: 3417-3421.
20. Hoey, B.M., Butler, J., Lea, J.S., and Sarna, T. 1988. A comparison of the free radical properties of several anthracycline anti-tumour drugs and some of their analogues. Free Radical. Res. Commun. 5(3): 169-176.
21. Ishii, T., and Fridovich, I. 1990. Dual effects of superoxide dismutase on the autoxidation of 1,4-naphthohydroquinone. Free Radical Biol. Med. 8: 21-24.
22. Jensen, R.A., Acton, E.M., and Peters, J.H. 1984a. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J. Cardiovasc. Pharmacol. 6: 186-200.
23. Jensen, R.A., Acton, E.M., and Peters, J.H. 1984b. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Cancer Res. 44: 4030-4039.
24. 2+ transients observed in cardiac myocytes isolated from the guinea pig heart. Can. J. Physiol. Pharmacol. 72: 622-631.
25. Keele, B.B., Jr., McCord, J.M., and Fridovich, I. 1971. Further characterization of bovine superoxide dismutase and its isolation from bovine heart. J. Biol. Chem. 246: 2875-2880.
26. Kontos, H.A., Wei, E.P., Ellis, E.F., Jenkins, L.W., Povlishock, J.T., Rove, G.T., and Hess, M.L. 1985. Appearance of superoxide anion radical in cerebral extracellular space during increased prostaglandin synthesis in cats. Circ. Res. 57: 142-151.
27. Lefrak, E.A., Pitha, J., Rosenheim, S., and Gottlieb, J.A. 1973. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32: 302-314.
28. Legha, S.S., Benjamin, R.S., MacKay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S.L., Blumenschein, G.R., and Freireich, E.J. 1982. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Int. Med. 96: 133-139.
29. Lewis, W., Galizi, M., and Puszkin, S. 1983. Compartmentalization of adriamycin and daunomycin in cultured chick cardiac myocytes: effects on synthesis of contractile and cytoplasmic proteins. Circ. Res. 53: 352-362.
30. Markey, B.A., Phan, S.H., Varani, J., Ryan, U.S., and Ward, P.A. 1990. Inhibition of cytotoxicity by intracellular superoxide dismutase supplementation. Free Radical Biol. Med. 9: 307-314.
31. McCord, J.M. 1993. Human disease, free radicals, and the oxidant/ antioxidant balance. Clin. Biochem. 26(5): 351-357.
32. McCord, J.M. 1995. Superoxide radical - controversies, contradictions, and paradoxes. Proc. Soc. Exp. Biol. Med. 209(2): 112-117.
33. Miwa, N., Kanaide, H., Meno, H., and Nakamura, M. 1986. Adriamycin and altered membrane functions in rat hearts. Br. J. Exp. Pathol. 67: 747-755.
34. Natale, N., Brambilla, M., Luchini, S., Martini, A., Moro, E., Pacciarini, M.A., Tamassia, V., Vago, G., and Trabattoni, A. 1981. 4′-Epi-doxorubicin and doxorubicin: toxicity and pharmacokinetics in cancer patients. In Current chemotherapy and immunotherapy. American Society for Microbiologists, Washington. pp. 1447-1449.
35. Nelson, S.K., Bose, S.K., and McCord, J.M. 1994. The toxicity of high-dose superoxide-dismutase suggests that superoxide can both initiate and terminate lipid-peroxidation in the reperfused heart. Free Radical Biol. Med. 16(2): 195-200.
36. Nicholls, P., and Schonbaum, G.R. 1963. Catalases. In The enzymes. Vol. 8. Edited by P.D. Boyer, H. Lardy, and K. Myrback. Academic Press, New York, London, pp. 363-408.
37. Ollinger, K., Buffinton, G.D., Ernster, L., and Cadenas, E. 1990. Effect of superoxide dismutase on the autoxidation of substituted hydro- and semi-naphthoquinones. Chem. Biol. Interact. 73: 53-76.
38. Pouna, P., Bonoron-Adele, S., Gouverneur, G., Tariosse, L., and Besse, P. 1995. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rabbit heart: comparison of new analogues versus doxorubicin. Cancer Chemother. Pharmacol. 35: 257-261.
39. Powis, G. 1989. Free radical formation by antitumor quinones. Free Radical Biol. Med. 6: 63-101.
40. Schinetti, M.L., Rossini, D., and Bertelli, A. 1987. Interaction of anthracycline antibiotics with human neutrophils: superoxide production, free radical formation and intracellular penetration. J. Cancer Res. Clin. Oncol. 113: 15-19.
41. Shepherd, M., Bruening, M., Auld, A.M., and Barritt, G.J. 1987. Effects of energy deprivation and hydrogen peroxide on contraction and myoplasmic free calcium concentrations in isolated myocardial muscle cells. Biochem. Med. Metab. Biol. 38: 195-204.
42. Siegfried, J.M., Burke, T.G., and Tritton, T.R. 1985. Cellular transport of anthracyclines by passive diffusion. Biochem. Pharmacol. 34: 593-598.
43. 2+ binding and lipid peroxidation but depresses myocardial function. Am. J. Physiol. 250: H419-H425.
44. Skovsgaard, T., and Nissen, N.I. 1982. Membrane transport of anthracyclines. Pharmacol. Ther. 18: 293-311.
45. Temma, K., Akera, T., Chugun, A., Kondo, H., Hagane, K., and Hirano, S. 1993. Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart. Eur. J. Pharmacol. 234(2-3): 173-181.
46. Torti, F.M., Bristow, M.M., Lum, B.L., Carter, S.K., Howes, A.E., Aston, D.A., Brown, B.W., Jr., Hannigan, J.F., Jr., Meyers, F.J., Mitchell, E.P., and Billingham, M.E. 1986. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 46: 3722-3727.
47. Wang, Y.X., and Korth, M. 1995. Effects of doxorubicin on excitation contraction coupling in guinea pig ventricular myocardium. Circ. Res. 76: 645-653.
48. Weenen, H., Lankelma, J., Penders, P.G.M., McVie, J.G., Ten Bokkel Huinink, W.W., de Planque, M.M., and Pinedo, H.M. 1983. Pharmacokinetics of 4′-epi-doxorubicin in man. Invest. New Drugs, 1: 59-64.
49. Winterbourn, C.C. 1981. Cytochrome c reduction by semiquinone radicals can be directly inhibited by superoxide dismutase. Arch. Biochem. Biophys. 209: 159-167.
50. Winterbourn, C.C., French, J.K., and Claridge, R.F.C. 1978. Superoxide dismutase as an inhibitor of reactions of semiquinone radicals. FEBS Lett. 94: 269-272.
51. Young, R.C., Ozols, R.F., and Myers, C.E. 1981. The anthracycline neoplastic drugs. New Engl. J. Med. 305: 139-153.
52. Yu, Z., Tibbits, G.F., and McNeill, J.H. 1994. Cellular functions of diabetic cardiomyocytes: contractility, rapid cooling contracture and ryanodine binding. Am. J. Physiol. 266: H2082-H2089.
53. Zbinden, B., and Brandle, E. 1975. Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127) and their derivatives in rats. Cancer Chemother. Rep. 59: 707-715.
54. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the side chain hydroxyl group. Biochim. Biophys. Acta, 884:326-336.